

B<sup>2</sup> 11. (Twice Amended) A vaccine according to claim 9, wherein [in which] the synthetic peptide [consisting essentially] of the amino acid sequence [SDGAVQPDGGQPAVRNERATG] of SEQ. I.D. NO. 2.

B<sup>3</sup> 15. (Twice Amended) A composition according to claim 13 wherein the peptide is selected from the group consisting of [/EHWSYGLRPGQHWSYGLRPG, SDGAVQPDGGQPAVRNERATG and RAISSWKQRNRWEWPRD] SEQ. I.D. NO.1, SEQ. I.D. NO. 2 and SEQ. I.D. NO. 3.

B<sup>4</sup> 18. (Twice Amended) A composition according to claim 16 wherein the peptide is selected from the group consisting of [/EHWSYGLRPGQHWSYGLRPG, SDGAVQPDGGQPAVRNERATG and RAISSWKQRNRWEWPRD] SEQ. I.D. NO.1, SEQ. I.D. NO. 2 and SEQ. I.D. NO. 3.

B<sup>5</sup> 21. (Twice Amended) A method according to claim 20 wherein the peptide is selected from the group consisting of [/EHWSYGLRPGQHWSYGLRPG, SDGAVQPDGGQPAVRNERATG and RAISSWKQRNRWEWPRD] SEQ. I.D. NO. 1, SEQ. I.D. NO. 2 and SEQ. I.D. NO. 3.

If questions exist after entry of the foregoing, the Office is kindly requested to contact applicants' representative at the address or telephone number given herein.

Respectfully submitted,

*Edgar C. Turner*  
REG. NO. 39,931

For : Allen C. Turner  
Registration No. 33,041  
Attorney for Applicants  
TRASK, BRITT & ROSSA  
P. O. Box 2550  
Salt Lake City, Utah 84110-2550  
Telephone: (801) 532-1922

Date: December 8, 1999

Enclosures: Substitute drawing (Fig. 1)  
Copy of Notice to Comply with Requirements for Patent Applications Containing  
Nucleotide Sequence and/or Amino Acid Sequence Disclosures  
Paper copy of Sequence Listing  
CRF copy of Sequence Listing  
Statement under 37 C.F.R. §§ 1.821(g) and 1.825

N:\2183\3898\Amendment.wpd